Profile data is unavailable for this security.
About the company
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
- Revenue in USD (TTM)17.00k
- Net income in USD-5.73m
- Incorporated1998
- Employees4.00
- LocationCreative Medical Technology Holdings Inc211 E. Osborn Rd.PHOENIX 85012United StatesUSA
- Phone+1 (480) 399-2822
- Websitehttps://creativemedicaltechnology.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Enzolytics Inc | 0.00 | -119.19k | 4.39m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
| Galmed Pharmaceuticals Ltd | 0.00 | -5.88m | 4.48m | 3.00 | -- | 0.1335 | -- | -- | -24.68 | -24.68 | 0.00 | 22.25 | 0.00 | -- | -- | 0.00 | -44.20 | -45.06 | -52.67 | -50.79 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.31 | -- | -- | -- |
| Theriva Biologics Inc | 0.00 | -22.27m | 4.52m | 21.00 | -- | 1.72 | -- | -- | -1.25 | -1.25 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -41.30 | -36.95 | -48.49 | -40.16 | -- | -- | -- | -- | -- | -- | 0.0056 | -- | -- | -- | 8.37 | -- | 95.91 | -- |
| Nymox Pharmaceutical Corp | 0.00 | -8.84m | 4.68m | 3.00 | -- | -- | -- | -- | -0.0966 | -0.0966 | 0.00 | -0.0339 | 0.00 | -- | -- | -- | -785.44 | -306.39 | -- | -749.37 | -- | -- | -- | -43,683.47 | -- | -157.57 | -- | -- | -- | -- | -34.49 | -- | -39.16 | -- |
| Exicure Inc | 500.00k | -8.17m | 4.76m | 5.00 | -- | 2.95 | -- | 9.52 | -4.72 | -4.72 | 0.2889 | 0.9323 | 0.0354 | -- | -- | 83,333.34 | -57.87 | -41.52 | -69.90 | -55.78 | -- | -- | -1,634.40 | -290.95 | -- | -- | 0.3827 | -- | -100.00 | -- | -555.07 | -- | -- | -- |
| National Graphite Corp | 0.00 | -1.97m | 4.80m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
| Portage Biotech Inc | 0.00 | -71.08m | 4.81m | 7.00 | -- | 1.92 | -- | -- | -68.81 | -68.81 | 0.00 | 2.39 | 0.00 | -- | -- | 0.00 | -137.29 | -30.53 | -143.21 | -40.02 | -- | -- | -- | -- | -- | -- | 0.02 | -- | -- | -- | 27.98 | -- | -- | -- |
| Raphael Pharmaceutical Inc | 0.00 | -1.40m | 4.86m | 0.00 | -- | -- | -- | -- | -0.0803 | -0.0803 | 0.00 | -0.0155 | 0.00 | -- | -- | -- | -1,134.41 | -- | -- | -- | -- | -- | -- | -- | -- | -139.10 | -- | -- | -- | -- | 61.76 | -- | -- | -- |
| Creative Medical Technology Holdings Inc | 17.00k | -5.73m | 4.91m | 4.00 | -- | 0.4939 | -- | 289.00 | -4.07 | -4.07 | 0.012 | 5.69 | 0.0015 | 1.00 | -- | 4,250.00 | -51.83 | -110.00 | -53.71 | -- | 60.00 | 65.82 | -33,716.41 | -7,961.14 | 20.20 | -- | 0.00 | -- | -89.84 | -40.86 | 47.88 | -- | -- | -- |
| Polyrizon Ltd | 0.00 | -997.00k | 5.05m | 1.00 | -- | -- | -- | -- | -0.2377 | -0.2377 | 0.00 | 0.0529 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.93 | 0.4048 | -- | -- | -- | 22.98 | -- | -- | -- |
| Windtree Therapeutics Inc | 0.00 | -11.38m | 5.12m | 15.00 | -- | 0.0991 | -- | -- | -0.7463 | -0.7463 | 0.00 | 17.65 | 0.00 | -- | -- | 0.00 | -32.86 | -44.51 | -40.15 | -48.38 | -- | -- | -- | -94,533.34 | -- | -- | 0.1612 | -- | -- | -- | 48.25 | -- | -- | -- |
| Burzynski Research Institute Inc | 0.00 | -1.54m | 5.39m | 2.00 | -- | -- | -- | -- | -0.0117 | -0.0117 | 0.00 | -0.0007 | 0.00 | -- | -- | -- | -89,888.89 | -15,304.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -45.74 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Aaron Wealth Advisors LLCas of 30 Sep 2024 | 19.57k | 1.46% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 17.63k | 1.32% |
| Two Sigma Advisers LPas of 30 Jun 2024 | 15.00k | 1.12% |
| Two Sigma Investments LPas of 30 Jun 2024 | 14.81k | 1.11% |
| Tower Research Capital LLCas of 30 Jun 2024 | 2.10k | 0.16% |
| Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 30 Jun 2024 | 108.00 | 0.01% |
| Osaic Fa, Inc. (Investment Management)as of 30 Jun 2024 | 100.00 | 0.01% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024 | 20.00 | 0.00% |
| Bank of America, NA (Private Banking)as of 30 Jun 2024 | 11.00 | 0.00% |
| BofA Securities, Inc.as of 30 Jun 2024 | 10.00 | 0.00% |
